[go: up one dir, main page]

PE20090823A1 - Purificacion de polipeptidos pegilados - Google Patents

Purificacion de polipeptidos pegilados

Info

Publication number
PE20090823A1
PE20090823A1 PE2008001193A PE2008001193A PE20090823A1 PE 20090823 A1 PE20090823 A1 PE 20090823A1 PE 2008001193 A PE2008001193 A PE 2008001193A PE 2008001193 A PE2008001193 A PE 2008001193A PE 20090823 A1 PE20090823 A1 PE 20090823A1
Authority
PE
Peru
Prior art keywords
sticked
erythropoyetin
mono
cation exchange
purification
Prior art date
Application number
PE2008001193A
Other languages
English (en)
Inventor
Josef Burg
Klaus Reichert
Axel Schroth
Harmut Schurig
Axel Wessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40120288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090823(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090823A1 publication Critical patent/PE20090823A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN METODO DE PURIFICACION DE UNA ERITROPOYETINA MONO-PEGILADA CONSISTENTE EN LA OBTENCION DE UNA SOLUCION QUE CONTIENE ERITROPOYETINA MONO-, POLI- Y NO-PEGILADADA MEDIANTE DOS ETAPAS CONSECUTIVAS DE CROMATOGRAFIA DE INTERCAMBIO CATIONICO Y LA RECUPERACION DE LA ERITROPOYETINA MONO-PEGILADA PURIFICADA EN EL SEGUNDO PASO DE LA CROMATOGRAFIA DE INTERCAMBIO CATIONICO. EL MATERIAL DE INTERCAMBIO CATIONICO ES SULFOPROPILO DE INTERCAMBIO CATIONICO Y LA SOLUCION ACUOSA TAMPONADA CONTIENE ACIDO FOSFORICO, ACIDO CITRICO, HISTIDINA O SALES DE LOS MISMOS
PE2008001193A 2007-07-17 2008-07-15 Purificacion de polipeptidos pegilados PE20090823A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07013959 2007-07-17

Publications (1)

Publication Number Publication Date
PE20090823A1 true PE20090823A1 (es) 2009-06-27

Family

ID=40120288

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001193A PE20090823A1 (es) 2007-07-17 2008-07-15 Purificacion de polipeptidos pegilados

Country Status (21)

Country Link
US (2) US8138317B2 (es)
EP (1) EP2178900B1 (es)
JP (2) JP5307808B2 (es)
KR (1) KR101163297B1 (es)
CN (1) CN101889023B (es)
AR (2) AR067537A1 (es)
AT (1) ATE556086T1 (es)
AU (1) AU2008277887B2 (es)
BR (1) BRPI0813830A2 (es)
CA (1) CA2692612C (es)
CL (1) CL2008002053A1 (es)
DK (1) DK2178900T3 (es)
ES (1) ES2386323T3 (es)
IL (1) IL202940A (es)
PE (1) PE20090823A1 (es)
PL (1) PL2178900T3 (es)
PT (1) PT2178900E (es)
RU (1) RU2476439C2 (es)
TW (1) TWI363060B (es)
WO (1) WO2009010270A2 (es)
ZA (1) ZA201000283B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002054A1 (es) * 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CA2736141C (en) * 2008-09-23 2018-03-20 F. Hoffmann-La Roche Ag Purification of erythropoietin
WO2011035282A1 (en) * 2009-09-21 2011-03-24 Ge Healthcare Bio-Sciences Ab Dual capture separation
KR101578586B1 (ko) * 2010-09-14 2015-12-17 에프. 호프만-라 로슈 아게 Peg화된 에리트로포이에틴의 정제 방법
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
CN105820232B (zh) * 2016-04-08 2019-05-17 昂德生物药业有限公司 单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
KR102820834B1 (ko) 2016-07-15 2025-06-13 에프. 호프만-라 로슈 아게 Ｐｅｇ화 에리트로포이에틴을 정제하기 위한 방법
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
SG11202005952TA (en) * 2017-12-29 2020-07-29 Hoffmann La Roche Process for providing pegylated protein composition
ES2905105T3 (es) * 2017-12-29 2022-04-07 Hoffmann La Roche Procedimiento para proporcionar una composición de proteína PEGilada
US20220017570A1 (en) * 2018-11-05 2022-01-20 Bristol-Meyers Squibb Company Method for purifying pegylated protein
WO2021072210A1 (en) * 2019-10-11 2021-04-15 Coherus Biosciences, Inc. Methods of purifying ranibizumab or a ranibizumab variant

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
AU635844B2 (en) 1989-11-06 1993-04-01 Cell Genesys, Inc. Production of proteins using homologous recombination
DK0505500T3 (da) 1989-12-22 1997-08-25 Applied Research Systems Modificering af endogen genekspression med regulatorisk element ved hjælp af homolog rekombination
FR2656531B1 (fr) 1989-12-29 1992-04-24 Sanofi Sa Promoteur artificiel pour l'expression de proteines dans le levure.
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
JP2826362B2 (ja) 1990-02-13 1998-11-18 三井化学株式会社 オレフィン重合用固体触媒の製造方法、オレフィン重合用固体触媒およびオレフィンの重合方法
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
CH686212A5 (de) 1992-03-07 1996-02-15 Buehler Ag Geb Verfahren und Vorrichtung zur Manipulation und Portionieren von langen Teigwaren.
DE4118912C1 (es) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
EP0536447A1 (en) 1991-10-11 1993-04-14 Koninklijke Emballage Industrie Van Leer B.V. Exposure meter for use with induction heat sealing of containers
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
EP0651761B1 (en) 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5264555A (en) 1992-07-14 1993-11-23 Enzon, Inc. Process for hemoglobin extraction and purification
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5437989A (en) 1992-12-30 1995-08-01 Hoffmann-La Roche Inc. Alcohol/aldehyde dehydrogenase from Gluconobacter oxydans DSM 4025 FERM BP-3812
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
WO1998058661A1 (en) 1997-06-23 1998-12-30 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
DE19734293A1 (de) 1997-08-08 1999-02-11 Boehringer Mannheim Gmbh Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
ATE342279T1 (de) 1999-01-26 2006-11-15 Neurosearch As Kaliumkanäle und für diese kaliumkanäle kodierende gene
BR0007781A (pt) 1999-01-29 2002-02-05 Hoffmann La Roche Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
DE50001030D1 (de) 1999-05-10 2003-02-13 Ciba Sc Holding Ag Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung zum Färben oder Bedrucken von natürlichen oder synthetischen Materialien
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
WO2001058957A2 (en) 2000-02-11 2001-08-16 Lexigen Pharmaceuticals Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CZ304855B6 (cs) * 2000-05-15 2014-12-10 F. Hoffmann-La Roche Ag Kapalná farmaceutická kompozice obsahující pegylovaný lidský erythropoetin, způsob její přípravy, léčivo pro léčení chorob korelujících s anemií při chronickém renálním selhání a zařízení s jejím obsahem
CN100528235C (zh) * 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
US6797299B2 (en) 2002-02-05 2004-09-28 Great Wall Enterprise Co., Ltd. Desalting method for nutritional supplements with animal protein
SE526227C2 (sv) 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
WO2004009627A1 (en) * 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
RU2318004C2 (ru) * 2002-07-24 2008-02-27 Ф.Хоффманн-Ля Рош Аг Добавки в виде полиалкиленгликолевой кислоты
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
WO2005021710A2 (en) 2003-06-02 2005-03-10 University Of Miami Chimeric molecules and methods of use
SE0401951D0 (sv) 2004-07-29 2004-07-29 Amersham Biosciences Ab Chromatography method
KR20070090023A (ko) * 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
CA2608393A1 (en) 2005-05-24 2006-11-30 Ge Healthcare Bio-Sciences Ab Regeneration of a chromatography matrix
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
GB2428018B (en) 2005-07-06 2010-07-28 Acco Uk Ltd Stapling device
US20070072795A1 (en) 2005-09-28 2007-03-29 Anton Haselbeck Treatment of neurodegenerative disorders
SI1931704T1 (sl) 2005-10-04 2011-04-29 Zymogenetics L L C Priprava in čiščenje IL-29
WO2008010061A2 (en) 2006-07-17 2008-01-24 Glenmark Pharmaceuticals S.A. 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.

Also Published As

Publication number Publication date
EP2178900A2 (en) 2010-04-28
ES2386323T3 (es) 2012-08-17
BRPI0813830A2 (pt) 2015-01-06
AU2008277887B2 (en) 2012-12-13
ATE556086T1 (de) 2012-05-15
JP5814978B2 (ja) 2015-11-17
CL2008002053A1 (es) 2009-05-22
IL202940A (en) 2015-07-30
CN101889023B (zh) 2013-03-20
WO2009010270A8 (en) 2010-04-29
DK2178900T3 (da) 2012-06-25
JP5307808B2 (ja) 2013-10-02
CA2692612A1 (en) 2009-01-22
RU2010105303A (ru) 2011-08-27
PL2178900T3 (pl) 2012-10-31
AU2008277887A1 (en) 2009-01-22
JP2010533664A (ja) 2010-10-28
KR20100072169A (ko) 2010-06-30
TW200914463A (en) 2009-04-01
AR112300A2 (es) 2019-10-16
KR101163297B1 (ko) 2012-07-05
CA2692612C (en) 2015-02-10
WO2009010270A3 (en) 2009-04-30
RU2476439C2 (ru) 2013-02-27
EP2178900B1 (en) 2012-05-02
AR067537A1 (es) 2009-10-14
US8138317B2 (en) 2012-03-20
ZA201000283B (en) 2011-06-29
JP2013189457A (ja) 2013-09-26
TWI363060B (en) 2012-05-01
US8889837B2 (en) 2014-11-18
WO2009010270A2 (en) 2009-01-22
US20110118448A1 (en) 2011-05-19
CN101889023A (zh) 2010-11-17
PT2178900E (pt) 2012-06-01
US20090118476A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
PE20090823A1 (es) Purificacion de polipeptidos pegilados
BR112018003733A2 (pt) absorvente para a remoção seletiva de sulfeto de hidrogênio a partir de um fluxo de fluido e processo para remoção de gases ácidos a partir de um fluxo de fluido
MX352823B (es) Formulaciones de proteinas que contienen aminoacidos.
UY26841A1 (es) Sales estables de ácido o-acetilsalicílico con aminoácidos básicos
MX386820B (es) Microcápsulas lipídicas que comprenden de preferencia un retinoide y composición que las contiene, su procedimiento de preparación y su uso en dermatología.
ECSP10010433A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CL2015000757A1 (es) Una proteina
AR061054A1 (es) Compuestos acidos de glicerilo y glicol
AR087929A1 (es) Metodo para preparar una composicion concentrada acuosa de glifosato teniendo una mezcla de sales de amina
CO7141413A2 (es) Proceso para la preparación de derivados de 2-(1-hidroxi-alquil)-cromen-4-ona ópticamente puros y opcionalmente sustituidos y su uso en la preparación de compuestos farmacéuticos
BR112014017321A8 (pt) método e sistema de exibição de página da web
AR127380A2 (es) Método para elaborar una solución acuosa de leucoíndigo libre de anilina o libre de anilina y n-metilanilina, solución estable acuosa de leucoindigo, método para su elaboración, aparato y uso
MX2013002948A (es) Composiciones farmaceuticas y nutraceuticas de acido abscisico.
CR11008A (es) Sales, composiciones liquidas acuosas que contienen sales de acido s-(+)- abscisico y metodos para su preparacion
CO7200278A2 (es) Preparación farmacéutica sólida que contiene levotiroxina
BR112015009122A2 (pt) processo em fase líquida anidra para produzir um álcool a partir de um ácido carboxílico
BR112015019196A2 (pt) método para reduzir consumo de energia por acoplamento térmico
BR112015006844A2 (pt) um elemento de contato com a pele que compreende ao menos uma substância sensibilizante termicamente resiliente
AR094035A1 (es) Estimulantes del colageno y su uso en el tratamiento de la piel
CL2013002073A1 (es) Procedimiento de preparación de albúmina que comprende ajustar concentración de proteína, ajustar ph, añadir ácido caprílico, aumentar la temperatura de la solución e incubar.
BR112016001779A2 (pt) comprimido em bicamada, e, processo
AR080324A1 (es) Plantas que tienen mejores rasgos relacionadas con el rendimiento y un metodo para producirlas
BR112015028918A2 (pt) remoção de impurezas de soluções de açúcar
UY32349A (es) Derivados de biaril-bencil-amina
AR054113A1 (es) Forma cristalina solida de pantoprazol como acido libre, sales derivadas del mismo y proceso para su preparacion

Legal Events

Date Code Title Description
FG Grant, registration